Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Kidney Int. 2018 Aug 6;94(4):756–772. doi: 10.1016/j.kint.2018.05.023

Figure 10.

Figure 10

XL-001 is effective in protecting against renal fibrosis and inflammation in an established obstructive nephropathy. (a) Experimental design. Red arrows indicate the time of UUO surgery. Green bars indicate XL-001 treatment. (b) Representative micrographs show kidney fibrotic lesions in different groups. Paraffin sections were used for Masson’s trichrome staining. Scale bar, 50 μm. (c) Western blot analyses show renal expression of fibronectin, α-SMA, β-catenin, PAI-1 and MMP-7 in different groups as indicated. Numbers (1 to 3) indicate individual animals in a given group. (d–h) Graphic presentations show the relative protein levels of fibronectin (d), α-SMA (e), β-catenin (f), PAI-1 (g) and MMP-7 (h) in different groups. *P < 0.05 versus controls; †P < 0.05 versus UUO alone (n = 5 to 6). (i) Western blotting analyses show p-p65 in different groups as indicated. Quantitative data (j) is presented. *P < 0.05 versus controls; †P < 0.05 versus UUO alone. (k, l) Graphic presentations show the relative levels of TNF-α (k) and RANTES (l) mRNA in different groups. (m) Representative micrographs show the immunofluorescence staining of mannose R expressions in the UUO kidneys after injections with vehicle or XL-001. Scale bar, 50 μm.